A systematic review of intravaginal testosterone for the treatment of vulvovaginal atrophy

Bell, Robin J., Rizvi, Farwa, Islam, Rakabul M. and Davis, Susan R. 2018, A systematic review of intravaginal testosterone for the treatment of vulvovaginal atrophy, Menopause: The Journal of the North American Menopause Society, vol. 25, no. 6, pp. 704-709, doi: 10.1097/gme.0000000000001052.

Attached Files
Name Description MIMEType Size Downloads

Title A systematic review of intravaginal testosterone for the treatment of vulvovaginal atrophy
Author(s) Bell, Robin J.
Rizvi, FarwaORCID iD for Rizvi, Farwa orcid.org/0000-0002-0485-8683
Islam, Rakabul M.
Davis, Susan R.
Journal name Menopause: The Journal of the North American Menopause Society
Volume number 25
Issue number 6
Start page 704
End page 709
Total pages 6
Publisher Lippincott, Williams & Wilkins
Place of publication Philadelphia, Pa.
Publication date 2018-06
ISSN 1072-3714
Keyword(s) intravaginal
vulvovaginal atrophy
Summary Objectives: Intravaginal testosterone has emerged as a potential treatment for vulvovaginal atrophy (VVA) in women, in general, and women taking an aromatase inhibitor (AI). A systematic review of the literature was undertaken to determine whether available clinical trial data support efficacy and safety of intravaginal testosterone for the treatment of VVA.Methods: Scopus, MEDLINE, EMBASE, and the Cochrane Library databases were systematically searched on July 26, 2017, for human studies published in English of clinical trials of intravaginal testosterone.Results: Six separate clinical trials were identified that ranged in size from 10 to 80 participants, with either single dose, or durations of 4 to 12 weeks. Only one study incorporated a double-blind design. Three studies were of women taking an AI.Taken together, the studies suggest that intravaginal testosterone may lower vaginal pH, increase the proportion of vaginal lactobacilli, and possibly improve the vaginal maturation index. The lack of a placebo treatment in four studies, and failure to adjust for baseline differences, resulted in uncertainty of the effect on sexual function. Safety remains uncertain because of the small number of women exposed, short study durations, and inconsistent and incomplete outcome reporting for sex steroid levels.Conclusion: Adequately powered double-blind, placebo-controlled clinical trials of intravaginal testosterone therapy are needed to establish both efficacy and safety.
Language eng
DOI 10.1097/gme.0000000000001052
Indigenous content off
Field of Research 11 Medical and Health Sciences
HERDC Research category C1 Refereed article in a scholarly journal
Copyright notice ©2018, North American Menopause Society
Persistent URL http://hdl.handle.net/10536/DRO/DU:30144885

Document type: Journal Article
Collections: Faculty of Health
School of Health and Social Development
Connect to link resolver
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 12 times in TR Web of Science
Scopus Citation Count Cited 0 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 21 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Wed, 04 Nov 2020, 12:35:18 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.